• 1
    Lurquin, C., Van Pel, A., Mariame, B., De Plaen, E., Szikora,J. P., Janssens, C., Reddehase, M. J., Lejeune, J. and Boon, T., Structure of the gene of tum transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989. 58:293303.
  • 2
    van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991. 254: 16431647.
  • 3
    Valmori, D., Levy, F., Miconnet, I., Zajac, P., Spagnoli, G. C., Rimoldi, D., Lienard, D., Cerundolo, V., Cerottini, J. C. and Romero, P., Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 2000. 164: 11251131.
  • 4
    Rosenberg, S. A., A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999. 10: 281287.
  • 5
    Levitsky, H. I., Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T cell tolerance. Cancer J. 2000. 6 Suppl. 3: S281290.
  • 6
    Ferber, I., Schonrich, G., Schenkel, J., Mellor, A. L., Hammerling, G. J. and Arnold, B., Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994. 263: 674676.
  • 7
    Kawai, K. and Ohashi, P. S., Immunological function of a defined T cell population tolerized to low-affinity self antigens. Nature 1995. 374: 6869.
  • 8
    Hausmann, S., Martin, M., Gauthier, L. and Wucherpfennig, K. W., Structural features of autoreactive TCR that determine the degree of degeneracy in peptide recognition. J. Immunol. 1999. 162: 338344.
  • 9
    Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M. and Sherman, L. A., Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 1998. 160: 643651.
  • 10
    Mullins, D. W., Bullock, T. N., Colella, T. A., Robila, V. V. and Engelhard, V. H., Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA A*0201-transgenic mice. J. Immunol. 2001. 167: 48534860.
  • 11
    Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. and Leder, P., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988. 54: 105115.
  • 12
    Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D. and Muller, W. J., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992. 89: 1057810582.
  • 13
    Shimizu, K., Fields, R. C., Giedlin, M. and Mule, J. J., Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 1999. 96: 22682273.
  • 14
    Dai, Z., Konieczny, B. T. and Lakkis, F. G., The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J. Immunol. 2000. 165: 30313036.
  • 15
    Gramaglia, I., Weinberg, A. D., Lemon, M. and Croft, M., Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998. 161: 65106517.
  • 16
    Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. and Croft, M., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001. 15: 445455.
  • 17
    Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C. and Shields, J., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 21602169.
  • 18
    Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L. and Chen, S. H., OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 2002. 6: 528536.
  • 19
    Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A. and Sherman, L. A., Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol. 1997. 52: 109118.
  • 20
    Vitiello, A., Mayesini, D., Furze, J., Sherman, L. A. and Chesnut, R. W., Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991. 173: 10071015.
  • 21
    Reilly, R. T., Gottlieb, M. B., Ercolini, A. M., Machiels, J. P., Kane, C. E., Okoye, F. I., Muller, W. J., Dixon, K. H. and Jaffee, E. M., HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 2000. 60: 35693576.
  • 22
    Kurt, R. A., Whitaker, R., Baher, A., Seung, S. and Urba, W. J., Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int. J. Cancer 2000. 87: 688694.
  • 23
    Reilly, R. T., Machiels, J. P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D. and Jaffee, E. M., The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001. 61: 880883.
  • 24
    Lollini, P. L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., Muller, W. J. and Nanni, P., Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 1998. 77: 937941.
  • 25
    Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C. and Sherman, L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 1997. 185: 833841.
  • 26
    Chen, Y., Hu, D., Eling, D. J., Robbins, J. and Kipps, T. J., DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998. 58: 19651971.
  • 27
    Cordaro, T. A., de Visser, K. E., Tirion, F. H., Schumacher, T. N. and Kruisbeek, A. M., Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 2002. 168: 651660.
  • 28
    Ercolini, A. M., Machiels, J. P., Chen, Y. C., Slansky, J. E., Giedlen, M., Reilly, R. T. and Jaffee, E. M., Identification and characterization of the immunodominant rat HER-2/neu MHC cClass I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 2003. 170: 42734280.
  • 29
    de Visser, K. E., Cordaro, T. A., Kioussis, D., Haanen, J. B., Schumacher, T. N. and Kruisbeek, A. M., Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur. J. Immunol. 2000. 30: 14581468.
  • 30
    De Smedt, T., Smith, J., Baum, P., Fanslow, W., Butz, E. and Maliszewski, C., Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 2002. 168: 661670.
  • 31
    Cuadros, C. D. A., Frost, G., Borgstrom, P. and Lustgarten, J., Cooperative effect between immunotherapy and antiangiogenic therapy results in effective tumor rejection in tolerant Her-2/neu mice. Cancer Res. 2003. 63: 58955901.